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Leukemia stem cells (LSCs), featuring unlimited self-renewal capacity and chemoresistance, are critical
cellular targets for new treatments to improve outcomes for acute myeloid leukemia (AML). In this issue of
Cell Stem Cell, Bruedigam et al. (2014) demonstrate that inhibition of telomerase is damaging to LSCs and
may represent a promising therapeutic approach in AML.Telomeres, the nucleoprotein complexes
with repetitive sequences that cap the
ends of eukaryotic chromosomes, are
essential for maintaining replicative ca-
pacity and genomic stability. The length
of telomeres shortens with each replica-
tion cycle, thereby limiting cellular life
span. Telomere maintenance is particu-
larly important for pluripotent stem cells
(Pucci et al., 2013) and multipotent stem
cells, including hematopoietic stem cells
(Wang et al., 2014), and is critical for
tissue homeostasis or regeneration.
The telomerase complex, composed of
a catalytic subunit telomerase reverse
transcriptase (TERT), a telomerase RNA
component (TERC), and a shelterin scaf-
fold can lengthen telomeric DNA through
a RNA-directed DNA polymerization
mechanism.
Telomere shortening is among the hall-
marks of aging and malignant cells. Once
a telomere is critically short, the chromo-
some ends elicit a double-strand-break-
like DNA damage response that results
in growth arrest and cell death. Age-
adjusted telomere length appears to be
significantly reduced in patients with
acute myeloid leukemia (AML), myelodys-
plastic syndrome (MDS), and chronicmyeloid leukemia (CML) as compared to
matched controls. Telomere shortening
may reflect the increased replication
required for leukemia development, but
it could also result from altered telomere
regulatory mechanisms. Indeed, telo-
merase mutations are associated with
myeloid malignancies, especially MDS
and AML (Townsley et al., 2014). Most
cancers have relatively short telomeres
but high levels of telomerase activity
compared to normal cells. Enhanced
telomerase activity likely represents an
important adaptive mechanism that
allows leukemia cells to continue to
replicate despite marked telomeric short-
ening. Telomerase activity has been
shown to be increased in CML and to be
required for leukemia development (Vice-
nte-Duen˜as et al., 2012). In addition, the
AML-related fusion genes MLL-AF4 and
AML1-ETO have been reported to upre-
gulate TERT expression (Gessner et al.,
2010).
AML originates from small populations
of leukemia stem cells (LSCs) that have
extensive self-renewing capacity but
tend to be resistant to chemotherapy
and contribute to relapse. It can be pre-
dicted that LSCs might be especiallydependent on telomerase activity to sus-
tain long-term replicative capacity and
that inhibition of telomerase activity may
be a potential approach to target LSC
self-renewal. In this issue of Cell Stem
Cell, Bruedigam and colleagues (Bruedi-
gam et al., 2014) examined the role of
telomerase in AML LSC function and
demonstrated an essential role for telo-
merase in the maintenance of functional
LSCs (Figure 1). Using mice depleted of
the RNA component of the telomerase
(Terc/) and a well-defined genetic
model of MLL-AF9-induced AML, they
showed that telomerase deficiency
greatly compromised self-renewal of
LSCs. Although AML developed with full
penetrance, suggesting that telomerase
is not essential for leukemia initiation,
telomerase deficiency greatly reduced
leukemia burden and the frequency of
functional LSCs measured in limiting dilu-
tion and secondary transplantation as-
says. Similar effects were detected using
additional AML models, including the
AML1-ETO/KRASG12C AML and BCR-
ABL/NUP98-HOXA9 AML, suggesting
that the effects of telomerase deficiency
were independent of the oncogenic
driver of AML. These results support anDecember 4, 2014 ª2014 Elsevier Inc. 673
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Figure 1. Telomerase Maintains Leukemia Stem Cell Long-Term
Self-Renewal
Telomerase inhibition either genetically (via Terc-deletion or shTERT) or
pharmacologically (via imetelstat) limits LSC self-renewal capacity through
cell cycle arrest, p53 activation, DNA damage, and apoptosis. Inhibition of
telomerase represents a promising approach to combat long-lived and che-
moresistant LSCs.
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activity in maintaining the
long-term self-renewing repli-
cation capacity of LSCs.
Terc/ LSCs demon-
strated chromosomal insta-
bility, which is marked by
increased end-to-end chro-
mosomal fusions and is
associated with increased
apoptosis and induction of
the p53 regulatory network.
Gene expression profiling
indicated that telomerase
deficiency in LSCs is associ-
ated with aberrant cell
cycling, DNA replication and
repair, and increased apo-ptosis. Notably, depletion of p53 using
shRNA partially restored colony formation
and rescued apoptosis, markedly ac-
celerated development of AML, and
completely rescued LSC serial-engraft-
ment capacity. These results indicate
that telomerase loss induces chromo-
somal instability and p53 activation that
results in loss of LSC function and leuke-
mia progression.
Importantly, the relevance of these find-
ings to human AML was also evaluated.
This demonstration is critical because of
well-recognized differences in telomere
dynamics inmice andmen. The telomeres
of most mice are 5 to 10 times longer
those of humans, despite having a life
span that is 30 times shorter, and this
discrepancy can result in significant
interspecies differences in response to
telomerase deficiency. Profiling human
AML patient samples revealed that a
gene signature associated with telome-
rase-deficient LSCs predicted favorable
outcome. Functional studies using
TERT-shRNA in the MM6 human AML
cell line confirmed that telomerase knock-
down inhibited LSC function in vitro and in
xenograft transplantation experiments.
Finally, imetelstat (GRN163L), a pharma-
cological telomerase inhibitor, showed
significant activity against primary human
AML cells. Imetelstat is a lipid-conjugated
13-mer oligonucleotide sequence that is
complementary to and binds to the RNA
template of telomerase (Herbert et al.,
2005). Administration of imetelstat pre-
vented AML development in primary
human xenografts and leukemia progres-
sion remained significantly delayed for
weeks after suspension of treatment.674 Cell Stem Cell 15, December 4, 2014 ª2Importantly, addition of imetelstat to
chemotherapy reduced or delayed leuke-
mia relapse compared to chemotherapy
alone. These results suggest that telome-
rase inhibition may be useful to prolong
remission and reduce relapse in AML.
These results are timely because imetel-
stat is currently being evaluated in clinical
trials for a number of malignancies,
including myelofibrosis, and trials in AML
are planned for the future.
The finding that LSCs rely on telome-
rase to maintain their extensive prolifera-
tive and self-renewal potential raises
important questions as to what defines
the sensitivity and responses to telome-
rase inhibition. It is noteworthy that
among the patients studied, the highest
sensitivity to imetelstat seemed to corre-
late with an enrichment of telomerase-
deficient gene expression signature. It
will be important to validate this signature
as a potential predictor of response in a
larger group of patients and in future clin-
ical trials. TERT is overexpressed in sub-
sets of AML such as t(8;21), inv(16), and
MLL-rearranged AML, and in the future it
will be important to determine the rela-
tionship between TERT expression and
sensitivity to telomerase inhibition. The
authors demonstrated that p53 contrib-
utes to the inhibition of LSC function but
additional p53-independent mechanisms
are also involved. Telomerase has been
implicated in additional noncanonical
functions such as transcriptional regula-
tion (Ye et al., 2014) and ribosomal DNA
transcription (Gonzalez et al., 2014). It
will be interesting to investigate whether
these functions of telomerase contribute
to the effects of telomerase inhibition. In014 Elsevier Inc.addition to telomerase-medi-
ated mechanisms, telomere
maintenance can be carried
out through Alternative
Lengthening of Telomeres
(ALT) and recombination-
based mechanisms. These
alternative mechanisms
could possibly influence the
sensitivity or confer resis-
tance to telomerase inhibition
and should be evaluated in
future studies. Finally, the
variability in telomere length
and telomerase activity
among different subclones of
LSCs in individual AML pa-
tients may affect their sus-ceptibility to telomerase inhibition and
could be an important determinant of
effectiveness in eliminating resistant LSC
populations.
Cancer stem cells constitute the roots
of a board spectrum of malignancies
and their resistance to existing anticancer
treatment represents a significant barrier
to successful disease eradication and
cure. Attacking the telomere protection
mechanism may represent an effective
approach to a variety of malignant stem
cells. Caution must be exercised to
consider potential long-term effects on
various normal tissue stem cells. Although
the current study did not reveal toxicities
of imetelstat toward normal tissues,
hepatotoxicity was identified as a poten-
tial concern in ongoing clinical trials.
Nevertheless, the study by Bruedigam
et al. elucidates the importance of telome-
rase in maintaining LSC self-renewal and
replication potential and supports the po-
tential application of telomerase-targeting
therapy to eliminate LSCs in AML and
possibly target other types of cancer
stem cells.REFERENCES
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In this issue of Cell Stem Cell, Savic et al. (2014) and Kim et al. (2014) provide insight into how global hetero-
chromatin condensation and LIN28 sequestration in embryonic stem cells are independent mechanisms
regulating pluripotency in the oft-overlooked nucleolus.Even though we have been aware of the
nucleolus for 180 years, and it is the
largest structure in the nucleus, it gets
little attention compared to the nucleus
(15,000 versus 374,000 cites). And much
less attention is paid to its role in epige-
netics (25 Pubmed citations) or hetero-
chromatin (800 citations) compared to its
role in ribosomal gene transcription.
That’s actually a bit strange for both his-
torical and biological reasons. Historical-
ly, because in the 1930s, Emil Heitz
described heterochromatic satellite re-
gions near the nucleolus, and Barbara
McClintock described the nucleolar-orga-
nizing region’s association with hetero-
chromatin. And biologically, because
most ribosomal genes are actually not
expressed in normal cells, and their
silencing by heterochromatin is necessary
to prevent chromosomal rearrangements
and excessive growth.
In this issue of Cell Stem Cell, two
papers now provide insight into indepen-
dent nucleolar mechanisms regulating
pluripotency in embryonic stem cells
(ESCs). Much as people now widely
accept the importance of the nuclear
membrane in organizing heterochromatin
structure, and emerging work connects
3D genome organization with regulation
of ESC fate (reviewed in Gorkin et al.,
2014), the nucleolus has so far gotten
the silent treatment in this area. The
work by Savic et al. addresses one mech-anism for heterochromatin formation dur-
ing lineage commitment as mouse ESCs
(mESCs) differentiate (Savic et al., 2014).
They specifically addressed the role of
the long noncoding RNA pRNA, which
is the mature form of the processed
2 kb long intergenic spacer (IGS)-rRNA,
already known to interact with nucleolar
repressor factor TIP5 in generating rDNA
heterochromatin. They first showed that
ribosomal DNA methylation is decreased
in induced pluripotent stem cells and het-
erochromatin marks H3K9me2/3 and
H3K27me3 increase during differentia-
tion; and the changes in both directions
are associated with expected increases
and decreases in transcription, respec-
tively. They then transfected mESCs with
pRNA, which led to TIP5 accumulation in
nucleoli and induced heterochromatic
rDNAwith an increase in CpGmethylation
and H3K9me2 at the rDNA promoter—
and mutagenesis experiments showed
that this was dependent on an intact
30-pRNA stem-loop structure, but not
the pRNA-TIP5 association itself. Thus
pRNA guides TIP5 to rDNA through its
hairpin structure and establishes ribo-
somal gene heterochromatin. Moreover
pRNA expression and TIP5 accumulation
led to a dramatic general increase in
condensed perinucleolar heterochromat-
in, as well as total levels of H3K9me2 in
the nucleus, an indicator of large-scale
heterochromatin formation.Another paper in this same issue, by
Kim et al., identifies a nucleolar targeting
mechanism by which a histone methyl-
transferase—normally these are involved
in the epigenetic machinery—affects plu-
ripotency in human ESCs (Kim et al.,
2014). The study addresses the mecha-
nism by which the key pluripotency
factor LIN28 represses processing of
let-7 miRNA (from the pri-let-7 to the
pre-let-7) to maintain self-renewal. In
the nucleus, LIN28 processing is less
well understood than in the cytoplasm,
which involves recruitment of TUT4/7
to induce oligo-uridylation of pre-let-7,
which appears to both prevent its Dicer-
induced processing into mature let-7
and render it susceptible to digestion by
the Dis3L2 exonuclease (reviewed in
Shyh-Chang and Daley, 2013). The au-
thors were pursuing a relatively recent
thread of studies on the nature and effect
of methylation of core pluripotency
factors. Specifically they investigated
the effect of SET7/9 monomethylase on
LIN28A, but not the paralogous LIN28B,
and identified the methylated residue
as lysine 135. Remarkably, the K135
methylation leads to nucleolar localiza-
tion of LIN28A and sequestration,
preventing LIN28A processing indepen-
dently of TUTase. Interestingly, the
K135 site of LIN28A is homologous to
the nucleolar localizing signal region of
LIN28B, which was already known toDecember 4, 2014 ª2014 Elsevier Inc. 675
